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Women are diagnosed with benign breast disease (BBD) when a 
biopsy of a palpable or a radiological abnormality of the breast 
reveals benign findings (1). BBD is a common diagnosis given that 
three to four benign breast biopsies are performed for every breast 
cancer diagnosed in the United States (2). Women with BBD have 
an increased risk of future breast cancer that can occur in either 
breast (3). To counsel women at elevated risk regarding options for 
breast cancer screening and risk reduction strategies, it is necessary 
to provide them an estimate of their individual breast cancer risk. 
To accurately predict a woman’s risk of breast cancer, multidisci-
plinary research including clinical, imaging, and tissue studies is 
needed to identify factors that contribute to breast cancer risk. In 
addition to multiple known clinical risk factors for breast cancer 
such as age, age at menarche, and family history, the two factors 
that are shown to be strongly associated with breast cancer risk are 
tissue-based assessment of lobular involution and a radiological 
marker of mammographic breast density (MBD) (4–7). We also 
recently reported an inverse association between lobular involu-
tion and MBD, leading to the question whether these two factors 
were independently associated with breast cancer risk (8).
The human breast glandular tissue has 15–20 lobes, each with 
many lobules that form the anatomical and functional units of the 
breast tissue. The lobules in turn, contain multiple acini that are the 
secretory structures of the breast (9). The lobules are surrounded 
by stroma and fat that vary in amount based on age and lactational 
status. As women age, the lobules undergo regression or involution 
(10). Age-related lobular involution has been described as physio-
logical atrophy of the breast, with a decrease in the number and size 
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  Background  Lobular involution, or age-related atrophy of breast lobules, is inversely associated with breast cancer risk, and 
mammographic breast density (MBD) is positively associated with breast cancer risk.
  Methods  To evaluate whether lobular involution and MBD are independently associated with breast cancer risk in women 
with benign breast disease, we performed a nested cohort study among women (n = 2666) with benign breast 
disease diagnosed at Mayo Clinic between January 1, 1985, and December 31, 1991 and a mammogram avail-
able within 6 months of the diagnosis. Women were followed up for an average of 13.3 years to document any 
breast cancer incidence. Lobular involution was categorized as none, partial, or complete; parenchymal pattern 
was classified using the Wolfe classification as N1 (nondense), P1, P2 (ductal prominence occupying <25%, or 
>25% of the breast, respectively), or DY (extremely dense). Hazard ratios (HRs) and 95% confidence intervals 
(CIs) to assess associations of lobular involution and MBD with breast cancer risk were estimated using ad-
justed Cox proportional hazards model. All tests of statistical significance were two-sided.
  Results  After adjustment for MBD, having no or partial lobular involution was associated with a higher risk of breast 
cancer than having complete involution (none: HR of breast cancer incidence = 2.62, 95% CI = 1.39 to 4.94; par-
tial: HR of breast cancer incidence = 1.61, 95% CI = 1.03 to 2.53; Ptrend = .002). Similarly, after adjustment for in-
volution, having dense breasts was associated with higher risk of breast cancer than having nondense breasts 
(for DY: HR of breast cancer incidence = 1.67, 95% CI = 1.03 to 2.73; for P2: HR of breast cancer incidence = 1.96, 
95% CI = 1.20 to 3.21; for P1: HR of breast cancer incidence = 1.23, 95% CI = 0.67 to 2.26; Ptrend = .02). Having a 
combination of no involution and dense breasts was associated with higher risk of breast cancer than having 
complete involution and nondense breasts (HR of breast cancer incidence = 4.08, 95% CI = 1.72 to 9.68; P = .006).
 Conclusion  Lobular involution and MBD are independently associated with breast cancer incidence; combined, they are 
associated with an even greater risk for breast cancer.
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of  acini  per  lobule  and  replacement  of  the  delicate  intralobular 
stroma with dense collagen and fatty tissue (10). In a study of lob-
ular involution among women with BBD, progressive degrees of 
lobular involution were associated with reduced breast cancer risk 
(4). However, the mechanism underlying the association between 
lobular involution and breast cancer risk is yet undefined.
MBD, which represents the proportion of tissues that appear 
white or dense on a mammogram, is a strong and consistent risk 
factor for breast cancer (5–7). MBD decreases as women age (11). 
It has been hypothesized that the association between mammo-
graphic density and increased breast cancer risk may be related to 
reduced  lobular  involution  of  breast  tissue  in  dense  breasts 
(5,12,13). In addition to age, MBD is associated with a variety   
of factors including body mass index (BMI), family history, and 
postmenopausal hormone (PMH) use (5,14).
Although lobular involution and MBD are both associated with 
breast cancer risk, it is not known whether they represent indepen-
dent risk factors for breast cancer. The extent of association of 
MBD and lobular involution with breast cancer risk can contribute 
to efforts to improve breast cancer risk prediction and may provide 
further insight into the biological mechanisms underlying the de-
velopment of breast cancer. In this report, we examined the asso-
ciations of lobular involution and MBD with breast cancer risk   
in  a  large  well-characterized  cohort  of  women  with  BBD  with 
long-term follow-up for breast cancer events.
Participants and Methods
Study Setting and Population
The Mayo Benign Breast Disease cohort included 9376 women, aged 
18–85 years, with no history of breast cancer, who were diagnosed 
with BBD at Mayo Clinic between January 1, 1967, and December 
31, 1991 (1). A woman was diagnosed with BBD when she had a bi-
opsy (surgical excision) of a palpable or radiographic abnormality in 
the breast that revealed benign findings. The extent of lobular invo-
lution was assessed in this benign breast tissue (described below). We 
studied a subcohort of women (n = 2666), nested in the Mayo BBD 
cohort, who were diagnosed with BBD between January 1, 1985, and 
December  31,  1991  (an  era  during  which  MBD  was  clinically 
assessed and recorded as the parenchymal pattern), and had a mam-
mogram within 6 months of the BBD diagnosis. Breast cancer events 
were  assessed  through  the  comprehensive  Mayo  medical  records 
(inpatient and outpatient) and a study-specific questionnaire (previ-
ously  described)  (1).  Women  who  subsequently  developed  breast 
cancer in this subcohort were considered case subjects.
All  study  protocol  procedures  and  patient  contact  materials 
were reviewed and approved by the Institutional Review Board of 
Mayo Clinic.
Assessment of Lobular Involution
To assess the extent of lobular involution, the study pathologists 
(D. W. Visscher and C. Reynolds) performed histopathological 
review of hematoxylin- and eosin-stained slides of breast tissue of 
all study participants, without knowledge of the original histology 
report or MBD pattern. This measure was assessed in the normal 
lobules on the slide containing the benign breast finding on the 
hematoxylin- and eosin-stained slide. The extent of lobular invo-
lution  was  classified  into  three  categories  as  none  (0%  lobules   
involuted),  partial  (1%–74%  lobules  involuted),  or  complete 
(≥75% lobules involuted) (6). In addition, the histological type of 
BBD  was  categorized  as  nonproliferative  disease,  proliferative 
disease without atypia, and atypical hyperplasia (1).
Assessment of MBD
MBD was measured clinically from all four views of the mammo-
gram—the  craniocaudal  and  mediolateral  oblique  views  of  the 
right and left breasts.  Wolfe’s parenchymal pattern was used to 
classify MBD into four parenchymal patterns based on the extent 
and type of density: N1—nondense, no ducts visible; P1—ductal 
prominence  occupying  less  than  a  fourth  of  the  breast;  P2—
prominent  ductal  pattern  occupying  more  than  a  fourth  of  the 
breast;  DY—homogenous  plaque-like  areas  of  extreme  density 
(15).  This  measure  of  MBD  has  high  inter-reader  agreement 
(16,17) and has been used in multiple previous studies and consis-
tently shown to be associated with breast cancer risk (18–28). This 
clinically obtained measure was documented by the radiologists 
and  retained  at  the  Mayo  Clinic,  starting  in  1985.  The  data 
extracted from these reports were analyzed for the current study.
Ascertainment of Risk Factor Information
Information  on  the  demographic  and  clinical  variables  including 
age, parity, family history of breast cancer, BMI, height, menopausal 
CONTEXT AND CAVEATS
Prior knowledge
The milk-forming lobules in human breasts undergo natural invo-
lution or regression with age. The lobules are believed to be the 
anatomic sites from which breast cancer originates. Increased lob-
ular  involution  is  associated  with  reduced  breast  cancer  risk. 
Increased  mammographic  breast  density  is  associated  with 
increased breast cancer risk and may be related to less involution.
Study design
The  study  examined  whether  lobular  involution  and  mammo-
graphic breast density, independently and combined, were associ-
ated with breast cancer risk in a cohort of women whose breast 
biopsy revealed benign findings and were followed up for an av-
erage of 13.3 years to document any breast cancer incidence.
Contribution
Lobular involution and mammographic breast density were inde-
pendently  associated  with  breast  cancer  risk.  Extremely  dense 
breasts and no lobular involution were associated with the highest 
risk of breast cancer compared with nondense breasts and com-
plete lobular involution.
Implications
A combination of the two independent risk factors, lobular involu-
tion, and mammographic breast density, may be used in devel-
oping breast cancer risk prediction models to estimate a woman’s 
risk of breast cancer.
Limitations
The different categories of lobular involution and mammographic 
breast density used in this study were subjective measures.
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status, and PMH therapy use was obtained from the Mayo medical 
record and questionnaires mailed to study participants or proxy, that 
is, next of kin of deceased patients (1). Family history of breast can-
cer was categorized as follows: strong—at least one first-degree rel-
ative with breast cancer before age 50 years, or two or more relatives 
with breast cancer with at least one being a first-degree relative; 
weak—any other family history of breast cancer; or none—no family 
history of breast cancer (1). Additional information regarding men-
opausal status was obtained from a clinical mammography database 
maintained at Mayo Clinic, a database of self-reported information 
gathered from patients at each mammogram visit.
Statistical Analysis
Descriptive  Statistics  and  Associations  With  Demographic 
and Clinical Variables.  For a quantitative summary of the data, 
we used frequencies and percentages for categorical variables, and 
means and standard deviation for continuous variables. To com-
pare  distributions  of  demographic  and  clinical  variables  across 
different categories of lobular involution and parenchymal pattern 
of MBD, we initially used x
2 tests of statistical significance. All 
variables that were univariately statistically significant were then 
included in a multivariable logistic regression model to assess the 
independent effects of these demographic and clinical variables. 
Separate logistic models were fit for lobular involution and for 
MBD parenchymal pattern.
Associations  of  Lobular  Involution  and  MBD  With  Breast 
Cancer  Risk.  The  duration  of  follow-up  was  calculated  as  the 
number of days from benign biopsy to the date of the diagnosis of 
breast cancer, death, or last contact. In addition, for women who 
had undergone a prophylactic mastectomy or who had a diagnosis 
of lobular carcinoma in situ, follow-up was censored at the corre-
sponding surgical or diagnosis date. The primary variables of in-
terest  included  the  two  exposure  variables—  lobular  involution 
(none, partial, and complete) and MBD parenchymal pattern (N1, 
P1,  P2,  and  DY).  The  following  established  breast  cancer  risk 
factors that are measured to correspond to each woman’s status at 
the time of the benign biopsy were examined as potential con-
founders: age (categorized as <45, 45–54, and ≥ 55 years) that was 
modeled as a categorical variable when directly assessing its asso-
ciation with breast cancer risk and as a continuous variable based 
on the original noninteger values when adjusting for its effect in 
other models; histological impression (categorized as nonprolifer-
ative  disease,  proliferative  disease  without  atypia,  and  atypical   
hyperplasia); parity (categorized as nulliparous and parous); meno-
pausal status (categorized as premenopausal and postmenopausal); 
PMH use (categorized as never use and ever use); family history of 
breast cancer (categorized as none, weak, and strong); and BMI 
(categorized  into  approximate  quartiles).  Crude  incidence  rates 
were calculated by dividing the number of observed events by the 
total number of person-years of observation, and 95% confidence 
intervals (CIs) for these rates were calculated based on the normal 
approximation to the Poisson distribution.
To assess associations between lobular involution, MBD, and 
potential confounding variables with breast cancer risk, we calcu-
lated  hazard  ratios  (HRs)  and  corresponding  95%  confidence 
intervals using Cox proportional hazards regression models, with 
time from the benign biopsy to breast cancer or last follow-up 
serving as the time scale. We formally evaluated the Cox regres-
sion proportional hazards assumptions for lobular involution and 
MBD hazard ratios by fitting and testing the corresponding expo-
sure × time interaction terms and found no evidence of model vio-
lations (P > .40 for each exposure variable). We used Wald x
2 tests 
to  examine  the  dose–response  effects  of  lobular  involution  and 
MBD  with  breast  cancer  risk  by  ordering  the  categories  from 
lowest (complete involution and N1) to highest (no involution and 
DY) hypothesized risk and including this ordered variable as a 1 df 
linear term in the Cox regression model. We first assessed associ-
ations with breast cancer risk after adjustment only for age because 
age is the strongest breast cancer risk factor for women in our 
cohort. Then, we simultaneously included all confounding vari-
ables in a multivariable Cox regression model. Finally, to examine 
the independent association of these two variables with breast can-
cer risk, in addition to adjusting for the risk factors listed above, we 
adjusted for MBD when assessing association for lobular involu-
tion and adjusted for lobular involution when assessing association 
for MBD.
To evaluate the potential modifying effects that lobular involu-
tion and MBD may have on each other’s association with breast 
cancer risk, we fitted and tested a lobular involution × MBD inter-
action term using the Cox regression model. We also examined the 
differences in breast cancer risk associated with combinations of 
specific  categories  of  lobular  involution  and  MBD.  For  these 
analyses, we recategorized MBD as a two-level variable: low den-
sity (N1 and P1), and high density (P2 and DY). When combined 
with the three-level measure of lobular involution, this resulted in 
six possible combinations of lobular involution and MBD. Because 
no inherent ordering of these joint lobular involution and MBD 
categories  from  lowest  to  highest  breast  cancer  risk  could  be 
assigned to the six combination values, statistical comparisons were 
made for five of these paired categories (complete involution and 
P2 or DY; partial involution and N1 or P1; partial involution and 
P2 or DY; no involution and N1 or P1 and; no involution and P2 
or DY); the combination of complete lobular involution with N1 
or  P1  parenchymal  pattern  of  MBD  serving  as  the  reference. 
Statistical significance was assessed for all five of these comparisons 
simultaneously  using  a  single  P  value  that  did  not  impose  any 
ordering among the estimated hazard ratios.
All statistical tests were two-sided. P values less than .05 were 
considered statistically significant, and all analyses were carried out 
using the SAS (SAS Institute, Inc, Cary, NC) software system.
Results
Patient Characteristics of the Nested Cohort Study
Between January 1, 1985, and December 31, 1991, 3271 women in 
the Mayo BBD cohort were diagnosed with BBD. A measure of 
MBD was available within 6 months of BBD diagnosis for 2666 
women (82%) who formed the study cohort. There were no statis-
tically significant differences between the study participants (n = 2666) 
and those not included because of lack of mammogram availability 
(n = 605), based on age, breast cancer case status, parity, BMI, or 
family history (data not shown). After a mean duration of 13.3 
years (standard deviation = 4.7) of follow-up, 172 of 2666 women jnci.oxfordjournals.org    JNCI | Articles 1719
Table 1. Association of demographic and clinical variables with risk of breast cancer*
Characteristic
No. of women  
(n = 2666), No. (%)
No. of women  
with breast cancer  
(n = 172)†
No. of  
person-years  
of follow-up HR (95% CI)‡ Ptrend§
Age at BBD diagnosis, y         <.001
  <45 696 (26.1) 29 9667 1.00||
  45–54 667 (25.0) 45 9507 1.58 (0.99 to 2.52)
  ≥55 1303 (48.9) 98 16 198 2.07 (1.37 to 3.14)
Histology         <.001
  Nonproliferative disease 1556 (58.4) 64 20 859 1.00||
  Proliferative disease without atypia 954 (35.8) 84 12 524 2.09 (1.51 to 2.89)
  Atypical Hyperplasia 156 (5.9) 24 1990 3.69 (2.30 to 5.91)
Parity         .23
  Nulliparous 358 (14.6) 27 4579 1.00||
  Parous 2087 (85.4) 134 27 899 0.75 (0.50 to 1.14)
  Missing¶ 221 11    
Body mass index, kg/m2         .91
  15–22 498 (25.2) 32 7396 1.00||
  23–25 506 (25.6) 32 7644 0.90 (0.55 to 1.47)
  26–29 523 (26.5) 38 7840 1.00 (0.62 to 1.61)
  30–66 449 (22.7) 29 6635 0.92 (0.55 to 1.52)
  Missing¶ 690 41    
Postmenopausal Hormone Use         .44
  Never 947 (44.0) 54 13 214 1.00||
  Ever 1205 (56.0) 85 17 740 1.15 (0.82 to 1.61)
  Missing¶ 514 33    
Menopause status         .61
  Premenopausal 796 (30.7) 37 11 065 1.00||
  Postmenopausal 1796 (69.3) 128 23 660 1.12 (0.69 to 1.81)
  Missing¶ 74 7    
Family history of breast cancer#         .004
  None 1542 (64.3) 93 20 901 1.00||
  Weak 509 (21.2) 36 7349 1.15 (0.78 to 1.70)
  Strong 349 (14.5) 39 4912 1.80 (1.24 to 2.61)
  Missing¶ 266 4    
*  Nested cohort study of women with benign breast disease (BBD) diagnosed at the Mayo Clinic between January 1, 1985, and December 31, 1991. CI = confi-
dence interval; HR = hazard ratio.
†  After a mean follow-up of 13.3 years, 172 of 2666 women developed breast cancer.
‡  Analysis of breast cancer risk was done using the Cox proportional hazards model. Association of risk with age at BBD diagnosis was unadjusted; all other associ-
ations with risk are adjusted for age.
§  Ptrend values were calculated using two-sided Wald test for trend.
||  Referent category in the Cox proportional hazards model.
¶  Subjects for whom information for that demographic or clinical variable was not available from questionnaires or medical records.
#  Strong—at least one first-degree relative with breast cancer before age 50 years, or two or more relatives with breast cancer with at least one being a first-
degree relative; weak—any other family of breast cancer; None—no family history of breast cancer.
(6.5%)  subsequently  developed  breast  cancer  (case  subjects).   
Table  1  shows  characteristics  of  the  study  cohort.  The  age 
distribution of the cohort showed that the groups of women aged 
less than 45 years or 45–54 years, each composed approximately 
one-fourth of the cohort, whereas women 55 years or older com-
posed 48.9% of the cohort. The mean age at biopsy was 54.7 years 
(95% CI = 54.2 to 55.2 years). A statistically significantly increased 
risk  of  breast  cancer  was  noted  in  women  who  were  55  years   
or older (HR = 2.07, 95% CI = 1.37 to 3.14, P < .001), who had 
atypical hyperplasia on biopsy (HR = 3.69, 95% CI = 2.30 to 5.91, 
P < .001), and who had strong family history for breast cancer 
(HR = 1.80, 95% CI = 1.24 to 2.61, P = .004). There were no 
statistically significant differences across case status with regard to 
parity (P = .23), BMI (P = .91), PMH use (P = .44), and menopause 
status (P = .61).
The distribution of patients by level of lobular involution and 
parenchymal patterns of MBD is shown in Table 2. Overall, 641 
of 2666 women (24%) showed complete involution, 359 of 2666 
women (13.5%) showed no involution, and 1666 of 2666 women 
(62.5%) showed partial involution. There was a large proportion 
(65%) of women with dense breasts (P2 and DY) in the cohort. For 
women with no involution, the majority (60.7%) had extremely 
dense (DY) pattern of mammographic density. However, among 
women with complete involution, the parenchymal patterns were 
almost equally represented in all four MBD categories (27.1%, 
19.7%, 27.5%, and 25.7%, for N1, P1, P2, and DY, respectively).
We also compared the distributions of demographic and clin-
ical variables across levels of lobular involution and parenchymal 
pattern  of  MBD.  In  univariate  analyses,  the  following  factors   
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age (≥55 years), nonproliferative histology, nulliparity, increased 
BMI, no PMH use, postmenopausal status, and no family history. 
The  following  factors  were  associated  with  less  dense  breast   
tissue—older age (≥55 years),  nonproliferative histology, parity, 
increased  BMI,  no  PMH  use,  postmenopausal  status,  and  no 
family  history.  After  including  these  variables  in  multivariable 
logistic regression analyses,  BMI and  PMH use were no longer 
associated  with  lobular  involution,  and  menopausal  status  and 
family history were no longer associated with parenchymal pat-
tern. All other variables remained statistically significant (P < .05) 
(data not shown) and were included in the models examining lob-
ular involution, MBD, and the risk of breast cancer.
Lobular Involution, MBD, and Breast Cancer Risk
Next  we  examined  the  association  of  lobular  involution  and   
parenchymal pattern of MBD with breast cancer risk in women 
diagnosed  with  BBD  (Table  3).  Age-adjusted  analyses  showed 
statistically significant associations of lobular involution (P < .001) 
and MBD (P = .002) with breast cancer risk. Adjusting for con-
founders (age, BBD histology, parity, BMI, menopausal status, and 
family history) in multivariable analyses revealed slightly attenu-
ated,  though  still  statistically  significant,  associations  of  lobular 
involution (P = .002) and MBD (P = .018) with risk. Additional 
adjustment for MBD did not change the association between lob-
ular involution and breast cancer risk (P = .002). Women with no 
or  partial  lobular  involution  showed  statistically  significantly 
increased risk of breast cancer compared with women with com-
plete involution (none: HR = 2.62, 95% CI = 1.39 to 4.94; partial: 
HR = 1.61, 95% CI = 1.03 to 2.53; Ptrend = .002), using the complete 
involution category as the referent. Similarly, additional adjust-
ment for lobular involution did not change the association between 
MBD and breast cancer risk. Women with dense breasts showed 
Table 2. Overall distribution of lobular involution and parenchymal pattern of mammographic breast density*
Wolfe parenchymal  
pattern†
Extent of lobular involution‡
None,‡ No. (%) Partial,‡ No. (%) Complete,‡ No. (%) Total, No. (%)
Overall 359 (13.5) 1666 (62.5) 641 (24.0) 2666 (100)
N1 56 (15.6) 325 (19.5) 174 (27.1) 555 (20.8)
P1 31 (8.6) 221 (13.3) 126 (19.7) 378 (14.2)
P2 54 (15.0) 412 (24.7) 176 (27.5) 642 (24.1)
DY 218 (60.7) 708 (42.5) 165 (25.7) 1091 (40.9)
*  Nested cohort study of women with benign breast disease diagnosed at the Mayo Clinic between January 1, 1985, and December 31, 1991.
†  Wolfe parenchymal pattern: N1—nondense, no ducts visible; P1—ductal prominence occupying less than a fourth of the breast; P2—prominent ductal pattern 
occupying more than a fourth of the breast; DY—homogenous plaque-like areas of extreme density.
‡  Extent of lobular involution was classified as none (0% lobules involuted), partial (1%–74% lobules involuted), and complete (≥75% lobules involuted).
Table 3. Age-adjusted and multivariable-adjusted risk of breast cancer by levels of lobular involution and parenchymal pattern of mam-
mographic breast density*
Characteristic
No. of  
women 
(%)
No. of  
women 
with breast  
cancer
No. of  
person-years  
of follow-up
Age adjusted†
Multivariable  
adjusted§
Multivariable  
adjusted||
HR (95% CI) Ptrend‡ HR (95% CI) Ptrend‡ HR (95% CI) Ptrend‡
Involution¶         <.001   .002   .002
Complete 641 (24.0) 28 7975 1.00#   1.00#   1.00#
Partial 1666 (62.5) 120 22 503 2.10 (1.37 to 3.23)   1.62 (1.03 to 2.53)   1.61 (1.03 to 2.53)
None 359 (13.5) 24 4895 2.96 (1.59 to 5.51)   2.62 (1.40 to 4.92)   2.62 (1.39 to 4.94)
Parenchymal 
  pattern**
        .002   .018   .022
N1 555 (20.8) 23 7255 1.00#   1.00#   1.00#
P1 378 (14.2) 19 4779 1.19 (0.65 to 2.18)   1.22 (0.66 to 2.24)   1.23 (0.67 to 2.26)
P2 642 (24.1) 56 8580 2.08 (1.28 to 3.37)   1.96 (1.20 to 3.21)   1.96 (1.20 to 3.21)
DY 1091 (40.9) 74 14 758 1.92 (1.19 to 3.10)   1.70 (1.05 to 2.77)   1.67 (1.03 to 2.73)
*  Nested cohort study of women with benign breast disease (BBD) diagnosed between January 1, 1985, and December 31, 1991 at the Mayo Clinic. All analyses 
were done using the Cox proportional hazards model. CI = confidence interval; HR = hazard ratio.
†  Age-adjusted univariate analysis.
‡  Ptrend values were calculated using two-sided Wald test for trend.
§   Multivariable analysis adjusting for age, BBD histology, body mass index (BMI), parity, menopause status, and family history.
||  Multivariable analysis adjusting for age, BBD histology, BMI, parity, menopause status and family history, and parenchymal pattern (for lobular involution) or 
lobular involution (for parenchymal pattern).
¶  Extent of lobular involution was classified as none (0% lobules involuted), partial (1%–74% lobules involuted), and complete (≥75% lobules involuted).
#  Referent category in the Cox proportional hazards model.
** Wolfe parenchymal pattern: N1—nondense, no ducts visible; P1—ductal prominence occupying less than a fourth of the breast; P2—prominent ductal pattern 
occupying more than a fourth of the breast; DY—homogenous, plaque-like areas of extreme density.jnci.oxfordjournals.org    JNCI | Articles 1721
Table 4. Risk of breast cancer for combinations of lobular involution and parenchymal pattern of mammographic breast density*
Combination of  
lobular involution†  
and parenchymal  
pattern‡
No. of  
women
No. of  
women with  
breast cancer
No. of  
person-years  
of follow-up
Incidence  
rate§  
(95% CI)
Age-adjusted,||  
HR (95% CI) P¶
Multivariable  
adjusted,#  
HR (95% CI) P¶
Complete† and N1  
  or P1‡
300 9 3644.46 247 (86 to 408) 1.00** <.001 1.00** .006
Complete† and P2 or  
  DY‡
341 19 4330.29 439 (242 to 636) 1.85 (0.84 to 4.10)   1.66 (0.75 to 3.70)
Partial† and N1 or P1‡ 546 28 7241.11 387 (244 to 530) 2.03 (0.95 to 4.31)   1.57 (0.73 to 3.36)
Partial† and P2 or DY‡ 1120 92 15 261.88 603 (480 to 726) 3.88 (1.92 to 7.83)   2.70 (1.32 to 5.53)
None† and N1 or P1‡ 87 5 1149.02 435 (54 to 817) 3.77 (1.22 to 11.6)   3.24 (1.05 to 9.98)
None† and P2 or DY‡ 272 19 3745.81 507 (279 to 736) 5.14 (2.18 to 12.1)   4.08 (1.72 to 9.68)
*  Nested cohort study of women with benign breast disease (BBD) diagnosed at the Mayo Clinic between January 1, 1985, and December 31, 1991. HR = hazard 
ratio; CI = confidence interval.
†  Extent of Lobular involution was classified as none (0% lobules involuted), partial (1 to 74% lobules involuted), or complete (≥75% lobules involuted).
‡  Wolfe parenchymal pattern: N1—nondense, no ducts visible; P1—ductal prominence occupying less than a fourth of the breast; P2—prominent ductal pattern 
occupying more than a fourth of the breast; DY—homogenous plaque-like areas of extreme density.
§  Crude incidence rates per 100 000 person-years. 95% confidence intervals calculated based on large sample normal approximation to the Poisson distribution.
║  Age-adjusted univariate analysis; analysis was done using the Cox proportional hazards model.
¶  P values were calculated using two-sided Wald test with 5 df.
#  Multivariable analysis adjusting for age, BBD histology, body mass index, parity, menopause status, and family history.
** Referent category in the Cox proportional hazards model.
statistically significantly increased risk of breast cancer compared 
with  women  with  nondense  breasts  (for  DY:  HR  =  1.67,  95%   
CI = 1.03 to 2.73; for P2: HR = 1.96, 95% CI = 1.20 to 3.21; for 
P1: HR = 1.23, 95% CI = 0.67 to 2.26; Ptrend = .02), using the N1 
category as the referent.
Furthermore, we examined the effect of combination of lobular 
involution and MBD categories on breast cancer risk (Table 4). 
Age-adjusted  analysis  showed  statistically  significantly  increased 
risk of breast cancer in women with no lobular involution and 
dense  breasts  (P2,  DY)  compared  with  women  with  complete 
involution and nondense breasts as the referent (HR = 5.14, 95% 
CI = 2.18 to 12.1). Adjusting for confounders (age, BBD histology, 
parity, BMI, menopause status, and family history) slightly attenu-
ated the risk association (HR = 4.08, 95% CI = 1.72 to 9.68). We 
also  found  that  when  looking  within  each  category  of  MBD, 
women  with  no  involution  were  at  higher  risk  compared  with 
those with complete involution (Table 4). Similarly, when we look 
within  each  category  of  involution,  women  with  dense  breasts   
were at higher risk compared with women with nondense breasts 
(Table 4). We found no evidence of effect modification between 
lobular involution and BBD (test for interaction, P = .60), consis-
tent  with  these  risk  factors  operating  independently  on  risk  of 
breast cancer.
Discussion
In this study, we investigated the independent contributions of 
lobular involution and MBD to breast cancer risk in a cohort of 
2666 women with BBD, followed for a mean of 13.3 years. This 
study, to our knowledge, is the first to show that lobular involution 
and  MBD  are  independently  associated  with  breast  cancer   
risk. Our findings also reveal that having a combination of dense 
breasts and no lobular involution was associated with higher breast 
cancer risk than having nondense or fatty breasts and complete 
involution.
Previously, our research team showed that progressive lobular 
involution  was  statistically  significantly  associated  with  reduced 
breast cancer risk (4). The association was present even within 
populations of women at high risk such as those at older age, with 
atypical hyperplasia, or strong family history of breast cancer. The 
decrease in risk with complete involution may simply reflect fewer 
numbers of epithelial cells at risk for malignant transformation, or 
shorter exposure of epithelial cells to carcinogenic influences (4). 
Further studies are needed to clarify the biological mechanisms 
underlying lobular involution and its contribution to breast cancer 
risk.
MBD is a strong risk factor for breast cancer and women with 
dense tissue occupying more than 60%–75% of the breast have a 
four- to six-fold increased risk of breast cancer compared with those 
who have little or no density (5,6). The few histological studies of 
MBD reported so far have suggested that both breast epithelium 
and stroma may contribute to MBD (29,30). The current study 
found that the majority (approximately 76%) of women with no 
involution  of  breast  tissue  had  dense  breasts  (P2,  DY  pattern). 
However, for women with complete lobular involution, there were 
fairly similar proportions of women in each of the MBD cate-
gories. One possible explanation is that as lobular involution oc-
curs, the atrophic breast glandular epithelium is initially replaced 
by stroma and later by fatty tissue. Hence, complete involution 
with dense tissue on mammography may indicate that although   
the epithelium is atrophic, the dense tissue reflects the stromal 
contribution to MBD.
The current analysis shows that women with greatest risk for 
breast cancer were those with no lobular involution and mammo-
graphically dense breasts (incidence rate = 507 per 100 000 person-
years, 95% CI = 279 to 736) compared with women with complete 1722   Articles | JNCI  Vol. 102, Issue 22  |  November 17, 2010
involution  and  mammographically  nondense  breasts  (incidence 
rate = 247 per 100 000 person-years, 95% CI = 86 to 408). Lack of 
lobular involution suggests an epithelial-rich environment (4). On 
the other hand, mammographically dense tissue, as noted earlier, 
has been thought to represent both epithelial and stromal compo-
nents  (29,30).  It  could  be  hypothesized  that  the  stromal-rich   
environment in mammographically dense breasts results in a pre-
ponderance of growth factors that may stimulate the epithelium in 
a non-involuted breast, setting the stage for malignant transforma-
tion (31). In fact, several studies have shown correlation between 
tissue-based  or  circulating  growth  factors  and  MBD  (32–34). 
Further tissue-based studies with inclusion of stromal markers are 
needed to clarify the risk mechanisms.
Our study findings have the potential to translate to improve-
ments in breast cancer risk prediction. Knowledge of a woman’s 
breast  cancer  risk  is  an  important  component  of  her  decision 
making regarding appropriate screening and use of risk reduction 
strategies  such  as  chemoprevention  (tamoxifen  or  raloxifene). 
The urgent need to accurately identify women at elevated risk of 
breast cancer has been emphasized in multiple reports (35,36). 
Currently, the commonly used breast cancer risk prediction tool, 
the Gail model, has been shown to provide useful risk stratifica-
tion when applied at the population level (37). However, in a 
study applying the Gail model to estimate risk for women with 
atypical  hyperplasia,  a  high-risk  subgroup  among  women  with 
BBD, the concordance between predicted and observed outcomes 
was low (concordance statistic = 0.50, 95% CI = 0.44 to 0.55) 
(38). In order to accurately classify women into high-risk or low-
risk groups, predictive risk markers must be identified and incor-
porated into risk models. Recent efforts to incorporate MBD into 
risk prediction models have shown slight improvement in dis-
criminatory accuracy (5,39,40). Our findings that lobular involu-
tion, a tissue-based marker, and MBD, a radiological marker, are 
independent risk factors for breast cancer, and that the combina-
tion of these factors can stratify risk, supports the potential for 
incorporation of both these markers in future breast cancer risk 
prediction models.
The strength of this study is that it was conducted in a large, 
well-characterized cohort of women with BBD, with information 
on both lobular involution and MBD, and long-term follow-up 
for breast cancer events. However, we acknowledge that our study 
has a few limitations. Both the parenchymal pattern measure of 
MBD  and  three-category  measure  of  lobular  involution  were 
subjective measures. However, the parenchymal pattern measure 
has been used in multiple prior studies and shown to be associated 
with breast cancer risk (15,19–21,28). Moreover, we are currently 
studying  ways  to  quantify  lobular  involution  (41),  which   
will likely strengthen any associations seen with risk. Although 
the study population was predominantly white, it was representa-
tive of the upper Midwest population of the United States, and   
we  acknowledge  the  need  for  continued  research  in  diverse 
populations.
In conclusion, we report that lobular involution and MBD are 
both risk factors for breast cancer, and that each provides unique 
information about breast cancer risk. These findings emphasize 
the potential for inclusion of these factors in future breast cancer 
risk prediction models.
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